Effect of pramlintide on symptom, catecholamine, and glucagon responses to hypoglycemia in healthy subjects.

Heise T, Heinemann L, Heller S, Weyer C, Wang Y, Strobel S, Kolterman O, Maggs D

Metabolism: clinical and experimental1 Sept 2004Cited by 21 (Europe PMC)

PMID15334389DOI10.1016/j.metabol.2004.04.010PepBankPUB-15334389

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialMechanism
In healthy subjects, autonomic symptom responses during hypoglycemia did not differ discernibly between pramlintide and placebo.
In plain wordsIn healthy subjects, autonomic symptoms during low blood sugar did not differ discernibly between pramlintide and placebo.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeAutonomic symptom response to hypoglycemia
Study
n = 18
Comparator
Placebo
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Studied dose
60 microg three times daily, then 16 microg/h infusion during clamp · subcutaneous, then intravenous during clamp · 5 consecutive days with study drug and clamp on day 6As given in this study (human).
Source sentences
Summary
Intraindividual and group mean responses showed that autonomic symptoms and plasma catecholamine and glucagon concentrations increased progressively during the clamp, with no discernible differences between pramlintide and placebo treatments.
3 context sentences(design, population, supporting numbers)
Summary · context
In a randomized, double-blind, placebo-controlled, crossover study, 18 healthy subjects without diabetes received subcutaneous premeal injections of either placebo or 60 microg pramlintide 3 times daily for 5 consecutive days.
Summary · context
On day 6, subjects received study drug with breakfast and, after a 7-hour fast, were connected to a Biostator for a 3-step, 3-hour clamp experiment (insulin infusion rate: 1.0 mU/kg/min; blood glucose targets: 70, 55, and 45 mg/dL).
Summary · context
An intravenous (IV) infusion of pramlintide (16 microg/h) or placebo was initiated at t = 60 minutes.
Report a problemFND-1533438901
02HumanRandomized controlled trialMechanism
In healthy subjects, epinephrine responses during hypoglycemia did not differ discernibly between pramlintide and placebo.
In plain wordsIn healthy subjects, epinephrine responses during low blood sugar did not differ discernibly between pramlintide and placebo.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeEpinephrine response to hypoglycemia
Study
n = 18
Comparator
Placebo
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
60 microg three times daily, then 16 microg/h infusion during clamp · subcutaneous, then intravenous during clamp · 5 consecutive days with study drug and clamp on day 6As given in this study (human).
Measurements
Epinephrine
202 pg/mL
pramlintide at 70 mg/dL glucose
Epinephrine
774 pg/mL
pramlintide at 55 mg/dL glucose
Epinephrine
2751 pg/mL
pramlintide at 45 mg/dL glucose
Epinephrine
233 pg/mL
placebo at 70 mg/dL glucose
Epinephrine
892 pg/mL
placebo at 55 mg/dL glucose
Epinephrine
2340 pg/mL
placebo at 45 mg/dL glucose
Source sentences
Summary
Intraindividual and group mean responses showed that autonomic symptoms and plasma catecholamine and glucagon concentrations increased progressively during the clamp, with no discernible differences between pramlintide and placebo treatments.
5 context sentences(design, population, supporting numbers)
Summary · context
Group means for catecholamines at 60 minutes were: epinephrine 233 +/- 42, 892 +/- 85, 2,340 +/- 302 and 202 +/- 25, 774 +/- 114, 2,751 +/- 404 pg/mL and
Summary · context
for placebo- and pramlintide-treated groups at 70, 55, and 45 mg/dL glucose, respectively.
Summary · context
In a randomized, double-blind, placebo-controlled, crossover study, 18 healthy subjects without diabetes received subcutaneous premeal injections of either placebo or 60 microg pramlintide 3 times daily for 5 consecutive days.
Summary · context
On day 6, subjects received study drug with breakfast and, after a 7-hour fast, were connected to a Biostator for a 3-step, 3-hour clamp experiment (insulin infusion rate: 1.0 mU/kg/min; blood glucose targets: 70, 55, and 45 mg/dL).
Summary · context
An intravenous (IV) infusion of pramlintide (16 microg/h) or placebo was initiated at t = 60 minutes.
Report a problemFND-1533438902
03HumanRandomized controlled trialMechanism
In healthy subjects, norepinephrine responses during hypoglycemia did not differ discernibly between pramlintide and placebo.
In plain wordsIn healthy subjects, norepinephrine responses during low blood sugar did not differ discernibly between pramlintide and placebo.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeNorepinephrine response to hypoglycemia
Study
n = 18
Comparator
Placebo
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
60 microg three times daily, then 16 microg/h infusion during clamp · subcutaneous, then intravenous during clamp · 5 consecutive days with study drug and clamp on day 6As given in this study (human).
Measurements
Norepinephrine
1278 pg/mL
pramlintide at 70 mg/dL glucose
Norepinephrine
1259 pg/mL
pramlintide at 55 mg/dL glucose
Norepinephrine
1580 pg/mL
pramlintide at 45 mg/dL glucose
Norepinephrine
1138 pg/mL
placebo at 70 mg/dL glucose
Norepinephrine
1236 pg/mL
placebo at 55 mg/dL glucose
Norepinephrine
1721 pg/mL
placebo at 45 mg/dL glucose
Source sentences
Summary
Intraindividual and group mean responses showed that autonomic symptoms and plasma catecholamine and glucagon concentrations increased progressively during the clamp, with no discernible differences between pramlintide and placebo treatments.
4 context sentences(design, population, supporting numbers)
Summary · context
norepinephrine 1,138 +/- 86, 1,236 +/- 77, 1,721 +/- 158 and 1,278 +/- 108, 1,259 +/- 109, 1,580 +/-136 pg/mL (+/- SEM) for placebo- and pramlintide-treated groups at 70, 55, and 45 mg/dL glucose, respectively.
Summary · context
In a randomized, double-blind, placebo-controlled, crossover study, 18 healthy subjects without diabetes received subcutaneous premeal injections of either placebo or 60 microg pramlintide 3 times daily for 5 consecutive days.
Summary · context
On day 6, subjects received study drug with breakfast and, after a 7-hour fast, were connected to a Biostator for a 3-step, 3-hour clamp experiment (insulin infusion rate: 1.0 mU/kg/min; blood glucose targets: 70, 55, and 45 mg/dL).
Summary · context
An intravenous (IV) infusion of pramlintide (16 microg/h) or placebo was initiated at t = 60 minutes.
Report a problemFND-1533438903
04HumanRandomized controlled trialMechanism
In healthy subjects, glucagon responses during hypoglycemia did not differ discernibly between pramlintide and placebo.
In plain wordsIn healthy subjects, glucagon responses during low blood sugar did not differ discernibly between pramlintide and placebo.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeGlucagon response to hypoglycemia
Study
n = 18
Comparator
Placebo
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
60 microg three times daily, then 16 microg/h infusion during clamp · subcutaneous, then intravenous during clamp · 5 consecutive days with study drug and clamp on day 6As given in this study (human).
Measurements
Glucagon
63 pmol/L
pramlintide at 70 mg/dL glucose
Glucagon
92 pmol/L
pramlintide at 55 mg/dL glucose
Glucagon
120 pmol/L
pramlintide at 45 mg/dL glucose
Glucagon
72 pmol/L
placebo at 70 mg/dL glucose
Glucagon
98 pmol/L
placebo at 55 mg/dL glucose
Glucagon
130 pmol/L
placebo at 45 mg/dL glucose
Source sentences
Summary
Intraindividual and group mean responses showed that autonomic symptoms and plasma catecholamine and glucagon concentrations increased progressively during the clamp, with no discernible differences between pramlintide and placebo treatments.
4 context sentences(design, population, supporting numbers)
Summary · context
Group means for glucagon were 72 +/- 6.3, 98 +/- 11.1, 130 +/- 14.7 and 63 +/- 3.6, 92 +/- 9.4, 120 +/- 16.0 pmol/L (+/- SEM) for placebo- and pramlintide-treated groups at 70, 55, and 45 mg/dL glucose, respectively.
Summary · context
In a randomized, double-blind, placebo-controlled, crossover study, 18 healthy subjects without diabetes received subcutaneous premeal injections of either placebo or 60 microg pramlintide 3 times daily for 5 consecutive days.
Summary · context
On day 6, subjects received study drug with breakfast and, after a 7-hour fast, were connected to a Biostator for a 3-step, 3-hour clamp experiment (insulin infusion rate: 1.0 mU/kg/min; blood glucose targets: 70, 55, and 45 mg/dL).
Summary · context
An intravenous (IV) infusion of pramlintide (16 microg/h) or placebo was initiated at t = 60 minutes.
Report a problemFND-1533438904

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.